Elicio Therapeutics, Inc.
ELTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $182,616 | $123,979 | $79,776 | $62,235 |
| - Cash | $20,611 | $22,088 | $18,351 | $17,618 |
| + Debt | $5,337 | $14,902 | $5,791 | $26,040 |
| Enterprise Value | $167,342 | $116,793 | $67,216 | $70,657 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$283 | $0 | -$278 | -$305 |
| % Margin | – | – | – | – |
| EBITDA | -$9,374 | -$10,086 | -$10,755 | -$13,465 |
| % Margin | – | – | – | – |
| Net Income | -$10,083 | -$10,561 | -$11,209 | -$14,004 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.6 | -0.66 | -0.87 | -1.15 |
| % Growth | 9.1% | 24.1% | 24.3% | – |
| Operating Cash Flow | -$11,086 | -$8,950 | -$10,119 | -$8,744 |
| Capital Expenditures | $0 | $0 | $0 | -$45 |
| Free Cash Flow | -$11,086 | -$8,950 | -$10,119 | -$8,789 |